

1. Record Nr.	UNINA9910818381003321
Titolo	Drug-drug interactions in pharmaceutical development // edited by Albert P. Li
Pubbl/distr/stampa	Hoboken, N.J., : Wiley-interscience, c2008
ISBN	9786612022067 9781282022065 1282022067 9780470187920 0470187921 9780470187913 0470187913
Edizione	[1st ed.]
Descrizione fisica	1 online resource (261 p.)
Collana	Wiley series in drug discovery and development
Altri autori (Persone)	LiA. P
Disciplina	615.7045 615/.7045
Soggetti	Drug interactions Drug development
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	DRUG-DRUG INTERACTIONS IN PHARMACEUTICAL DEVELOPMENT; CONTENTS; Preface; Contributors; 1 In Vitro Evaluation of Metabolic Drug-Drug Interactions: Concepts and Practice; 1.1 Introduction; 1.2 Mechanisms of Adverse Drug-Drug Interactions; 1.2.1 Pharmacological Interactions; 1.2.2 Pharmacokinetic Interactions; 1.3 Drug Metabolism; 1.3.1 Phase I Oxidation; 1.3.2 Phase II Conjugation; 1.4 CYP Isoforms; 1.5 Human In Vitro Experimental Systems for Drug Metabolism; 1.5.1 Hepatocytes; 1.5.2 Liver Postmitochondrial Supernatant (PMS); 1.5.3 Human Liver Microsomes; 1.5.4 Recombinant P450 Isoforms (rCYP) 1.5.5 Cytosol1.6 Mechanisms of Metabolic Drug-Drug Interactions; 1.7 Mechanism-Based Approach for Evaluation of Drug-Drug Interaction Potential; 1.7.1 Metabolic Phenotyping; 1.7.2 Evaluation of Inhibitory Potential for Drug-Metabolizing Enzymes; 1.7.3 Induction Potential for Drug-Metabolizing Enzymes; 1.8 Experimental Approaches for In Vitro Evaluation of Drug-Drug Interaction Potential; 1.8.1 Study 1: Metabolic

Phenotyping 1-Metabolite Identification; 1.8.2 Study 2: Metabolic Phenotyping 2-Identification of Major Metabolic Pathways
1.8.3 Study 3: Metabolic Phenotyping 3-Identification of P450 Isoform Pathways (P450 Phenotyping)1.8.4 Study 4: CYP Inhibitory Potential; 1.8.5 Study 5: Enzyme Induction Potential; 1.8.6 Study 6: In Vitro Empirical Drug-Drug Interactions; 1.9 Data Interpretation; 1.9.1 Pathway Evaluation; 1.9.2 P450 Inhibition; 1.9.3 P450 Induction; 1.10 Conclusion; References; 2 In Vitro Approaches to Anticipating Clinical Drug Interactions; 2.1 In Vitro Systems for Human CYP450 Metabolism; 2.1.1 Incubation Buffer (pH and Ionic Strength); 2.1.2 MgCl(2) and Cytochrome b(5); 2.1.3 Nonspecific Binding
2.1.4 Organic Solvents and Excipients2.2 Analysis of Data from In Vitro Systems; 2.2.1 Linear Transformation of Michaelis-Menten Equation (Lineweaver-Burk and Eadie-Hofstee); 2.2.2 Nonlinear Regression Analysis of Hyperbolic Kinetic Data; 2.2.3 Consideration of Non-Michaelis-Menten Kinetics; 2.3 Use of In Vitro Kinetic Data to Predict In Vivo Clearance; 2.3.1 Calculation of In Vitro (Predicted) Hepatic Clearance; 2.3.2 Comparison of In Vitro (Predicted) with In Vivo Hepatic Clearance; 2.4 Use of In Vitro Kinetic Data to Predict Drug-Drug Interactions
2.4.1 Choice of Probe Substrates for Inhibition Studies2.4.2 Determining the Mechanism of CYP450 Inhibition; 2.4.3 Prediction of In Vivo Drug-Drug Inhibition Interactions from In Vitro Data; 2.5 Consideration of Non-CYP Enzymatic Systems; 2.5.1 Flavin-Containing Monooxygenase (FMO); 2.5.2 UDP-glucuronosyltransferase (UGT); 2.5.3 Sulfotransferase (SULT); 2.5.4 N-Acetyltransferase (NAT); 2.5.5 Methyltransferase; 2.5.6 Epoxidase Hydrolase; 2.5.7 Aldehyde Oxidase and Dehydrogenase; 2.5.8 Glutathione-S-transferase (GST); 2.6 Summary; 2.7 Acknowledgments; References
3 Inhibition of Drug-Metabolizing Enzymes and Drug-Drug Interactions in Drug Discovery and Development

Sommario/riassunto

Drug-Drug Interactions in Pharmaceutical Development comprehensively reviews the relevant science, industrial practice, and regulatory agency positions on drug-drug interactions. It focuses on the evaluation of potential drug-drug interactions, allowing researchers to address risk factors before a drug is put to market. The book covers both clinical and nonclinical aspects for understanding drug-drug interactions as well as in vitro and in vivo studies for use in studying interactions at the drug discovery stage.

2. Record Nr.	UNINA9910397953403321
Autore	Groinig Maria, Dr.
Titolo	Bildung als Perspektive für Care Leaver? : Bildungschancen und Bildungswege junger Erwachsener mit Kinder- und Jugendhilfeeerfahrung // Maria Groinig, Wolfgang Hagleitner, Thomas Maran, Stephan Sting
Pubbl/distr/stampa	Leverkusen, : Verlag Barbara Budrich, 2019
ISBN	9783847412557 3847412558
Edizione	[1st ed.]
Descrizione fisica	1 online resource (229 pages)
Collana	Schriftenreihe der ÖFEB-Sektion Sozialpädagogik
Disciplina	362.7
Soggetti	Heimkinder SOS-Kinderdörfer Pflegekinder Erwachsene Heimkinder Adoleszenz Kinder- und Jugendhilfe (formale) Bildung informelle Bildung Statuspassage Bildungsverläufe Ausbildungschancen Sozialpädagogik
Lingua di pubblicazione	Tedesco
Formato	Materiale a stampa
Livello bibliografico	Monografia
Sommario/riassunto	Im Buch werden die Ergebnisse einer Studie vorgestellt, mit deren Hilfe erstmalig systematische Erkenntnisse zur Bildungs-, Ausbildungs- und Berufssituation von Care Leavern in Österreich gewonnen wurden und in der mit Hilfe quantitativer und qualitativer Forschungszugänge das Zusammenwirken von Bildungsverläufen und sozialen Kontextbedingungen des Aufwachsens untersucht wurde.

Der Band gibt Einblick in Lebensumstände von Care Leavern mit dem Ziel, Bildungsbenachteiligungen zu verringern und Teilhabechancen zu vergrößern. Die Ergebnisse sind von Nutzen, sowohl, um weitere Unterstützungsleistungen nach der Volljährigkeit von Care Leavern zu begründen, als auch, um allgemeine sozialpolitische Regelungen in Bezug auf die Chancengleichheit und Bildungsteilhabe weiterzuentwickeln und die Praxis der Fremdunterbringung entsprechend anzupassen. ÖJS Österreichisches Jahrbuch für Soziale Arbeit, 2021
